TribLIVE

| Business

 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Mylan to buy Indian generic drug maker for $1.6B

Email Newsletters

Click here to sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

Related .pdfs
Can't view the attachment? Then download the latest version of the free, Adobe Acrobat reader here:

Get Adobe Reader

'American Coyotes' Series

Traveling by Jeep, boat and foot, Tribune-Review investigative reporter Carl Prine and photojournalist Justin Merriman covered nearly 2,000 miles over two months along the border with Mexico to report on coyotes — the human traffickers who bring illegal immigrants into the United States. Most are Americans working for money and/or drugs. This series reports how their operations have a major impact on life for residents and the environment along the border — and beyond.

Wednesday, Feb. 27, 2013, 5:15 p.m.
 

Generic drug maker Mylan Inc. said on Wednesday that it will acquire an Indian maker of generic injectable medicines for $1.6 billion, expanding its manufacturing capacity and portfolio in an area of generics in which quality concerns have led to a shortage of treatments.

The all-cash deal for Agila Specialties Private Ltd. also will make Mylan a bigger player in generic injectables and increase its footprint in emerging markets, especially in Brazil where the India-based company it is acquiring gets a significant amount of business.

“Agila will bring us one of the most state-of-the-art, high-quality injectables manufacturing platforms in the industry,” said Heather Bresch, chief executive of Cecil-based Mylan.

Along with its nine facilities in India, Brazil and Poland — eight of which are approved by the Food and Drug Administration to make drugs for the U.S. market — Agila gives Mylan more than 300 products.

Mylan's portfolio of injectables includes more than 500 medicines, and it has two injectable manufacturing plants in Ireland and India. Injectables include antibiotics and treatments for cancer among other drugs.

Agila is a subsidiary of Strides Arcolab Ltd., an Indian pharmaceutical company, which also could receive up to $250 million in additional payments if it meets certain unspecified conditions.

Bresch told analysts on a conference call announcing the deal and the company's fourth-quarter earnings that Agila's plants will make it easier for Mylan to better fill America's unmet need for sterile injectable drugs.

The FDA has estimated that shortages of sterile injectables account for 80 percent of drug shortages in the United States, and about 40 percent of those shortages are because of quality problems, Bresch said.

The expanded manufacturing capacity and large portfolio of more than 800 injectable medicines will position Mylan to meet demand from a global generic injectables market that is expected to grow by 13 percent a year through 2017, the company said.

Brazil is a growing market “that Mylan has been looking at for some time,” Mylan President Rajiv Malik said. About 27 percent of Agila's sales come from the South American country of nearly 200 million people.

Mylan expects the deal to close in the fourth quarter and immediately begin to add to its earnings.

The company reported fourth-quarter earnings of $162.0 million, or 39 cents a share, up from $129.5 million, or 30 cents a share, in the same period a year ago.

The quarter capped what Bresch said was “our best year to date.”

For the full year, net income was $640.9 million, or $1.52 a share, compared with $536.8 million, or $1.22 a share, in 2011. For 2013, Mylan is predicting adjusted earnings per share of $2.75 to $2.95.

The announcements came after stock markets closed on Wednesday.

Alex Nixon is a staff writer for Trib Total Media.

He can be reached at 412-320-7928 or anixon@tribweb.com.

Add Alex Nixon to your Google+ circles.

Subscribe today! Click here for our subscription offers.

 

 

 


Show commenting policy

Most-Read Business Headlines

  1. $2-per-gallon gas expected by year’s end, but not in Western Pa.
  2. Weak earnings drag energy sector lower
  3. Hillary Clinton calls out GOP on trade embargo on Cuba
  4. Muni bond funds stressed
  5. ATI to benefit from WTO ruling against China in steel case
  6. Cost-cutting at Kraft Heinz extends to refrigerator
  7. Range Resources cuts workforce 11%
  8. Kennametal expects to consolidate plants as it shrinks manufacturing in continuing streamlining; profit drops
  9. GNC to convert more stores to franchises as sales, profits slip
  10. Steelworkers union says U.S. Steel using downturn to ‘gut’ contract
  11. PPG puts brand 1st in strategy to reach commercial paint market